Form 20-F - Annual and transition report of foreign private issuers [Sections 13 or 15(d)]:
SEC Accession No. 0001144204-09-019131
Filing Date
2009-04-06
Accepted
2009-04-06 16:51:10
Documents
13
Period of Report
2008-12-31

Document Format Files

Seq Description Document Type Size
1 v145414_20f.htm 20-F 2782467
2 GRAPHIC logo.jpg GRAPHIC 11040
3 v145414_ex10-37.htm EX-10.37 508008
4 v145414_ex10-43.htm EX-10.43 281388
5 v145414_ex10-44.htm EX-10.44 232641
6 v145414_ex10-45.htm EX-10.45 39177
7 v145414_ex21-1.htm EX-21.1 5466
8 v145414_ex23-1.htm EX-23.1 3836
9 v145414_ex23-2.htm EX-23.2 4621
10 v145414_ex31-1.htm EX-31.1 9513
11 v145414_ex31-2.htm EX-31.2 9765
12 v145414_ex32-1.htm EX-32.1 9612
13 v145414_ex99-1.htm EX-99.1 11991
  Complete submission text file 0001144204-09-019131.txt   3915225
Mailing Address 711 EXECUTIVE BOULEVARD SUITE Q VALLEY COTTAGE NY 10989
Business Address 711 EXECUTIVE BOULEVARD SUITE Q VALLEY COTTAGE NY 10989 972-8-930-4440
XTL BIOPHARMACEUTICALS LTD (Filer) CIK: 0001023549 (see all company filings)

EIN.: 000000000
Type: 20-F | Act: 34 | File No.: 000-51310 | Film No.: 09735563
SIC: 2834 Pharmaceutical Preparations